6
Participants
Start Date
September 1, 2021
Primary Completion Date
November 10, 2021
Study Completion Date
November 10, 2021
PIPE-307
"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
Hammersmith Medicines Research, London
Lead Sponsor
Contineum Therapeutics
INDUSTRY